These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34164554)

  • 1. Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease.
    Deterding R; Griese M; Deutsch G; Warburton D; DeBoer EM; Cunningham S; Clement A; Schwerk N; Flaherty KR; Brown KK; Voss F; Schmid U; Schlenker-Herceg R; Verri D; Dumistracel M; Schiwek M; Stowasser S; Tetzlaff K; Clerisme-Beaty E; Young LR
    ERJ Open Res; 2021 Apr; 7(2):. PubMed ID: 34164554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
    Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
    Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nintedanib in children and adolescents with fibrosing interstitial lung diseases.
    Deterding R; Young LR; DeBoer EM; Warburton D; Cunningham S; Schwerk N; Flaherty KR; Brown KK; Dumistracel M; Erhardt E; Bertulis J; Gahlemann M; Stowasser S; Griese M;
    Eur Respir J; 2023 Feb; 61(2):. PubMed ID: 36041751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.
    Cottin V; Richeldi L; Rosas I; Otaola M; Song JW; Tomassetti S; Wijsenbeek M; Schmitz M; Coeck C; Stowasser S; Schlenker-Herceg R; Kolb M;
    Respir Res; 2021 Mar; 22(1):84. PubMed ID: 33726766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial.
    Inoue Y; Suda T; Kitamura H; Okamoto M; Azuma A; Inase N; Kuwana M; Makino S; Nishioka Y; Ogura T; Takizawa A; Ugai H; Stowasser S; Schlenker-Herceg R; Takeuchi T
    Respir Med; 2021 Oct; 187():106574. PubMed ID: 34564020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
    Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
    Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
    Flaherty KR; Wells AU; Cottin V; Devaraj A; Walsh SLF; Inoue Y; Richeldi L; Kolb M; Tetzlaff K; Stowasser S; Coeck C; Clerisme-Beaty E; Rosenstock B; Quaresma M; Haeufel T; Goeldner RG; Schlenker-Herceg R; Brown KK;
    N Engl J Med; 2019 Oct; 381(18):1718-1727. PubMed ID: 31566307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial.
    Cottin V; Martinez FJ; Jenkins RG; Belperio JA; Kitamura H; Molina-Molina M; Tschoepe I; Coeck C; Lievens D; Costabel U
    Respir Res; 2022 Apr; 23(1):85. PubMed ID: 35392908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.
    Matteson EL; Kelly C; Distler JHW; Hoffmann-Vold AM; Seibold JR; Mittoo S; Dellaripa PF; Aringer M; Pope J; Distler O; James A; Schlenker-Herceg R; Stowasser S; Quaresma M; Flaherty KR;
    Arthritis Rheumatol; 2022 Jun; 74(6):1039-1047. PubMed ID: 35199968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial.
    Inoue Y; Wells AU; Song JW; Xu Z; Kitamura H; Suda T; Okamoto M; Müller H; Coeck C; Rohr KB; Kolb M; Brown KK
    Respirology; 2023 May; 28(5):465-474. PubMed ID: 36642509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial.
    Ogura T; Suda T; Inase N; Nishioka Y; Azuma A; Okamoto M; Takizawa A; Ito T; Rohr KB; Inoue Y
    Respir Investig; 2022 Nov; 60(6):787-797. PubMed ID: 35927208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Distler O; Highland KB; Gahlemann M; Azuma A; Fischer A; Mayes MD; Raghu G; Sauter W; Girard M; Alves M; Clerisme-Beaty E; Stowasser S; Tetzlaff K; Kuwana M; Maher TM;
    N Engl J Med; 2019 Jun; 380(26):2518-2528. PubMed ID: 31112379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
    Makino S
    Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).
    Distler O; Brown KK; Distler JHW; Assassi S; Maher TM; Cottin V; Varga J; Coeck C; Gahlemann M; Sauter W; Schmidt H; Highland KB;
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):75-81. PubMed ID: 28664834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial.
    Flaherty KR; Wells AU; Cottin V; Devaraj A; Inoue Y; Richeldi L; Walsh SLF; Kolb M; Koschel D; Moua T; Stowasser S; Goeldner RG; Schlenker-Herceg R; Brown KK;
    Eur Respir J; 2022 Mar; 59(3):. PubMed ID: 34475231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of nintedanib by inclusion criteria for progression of interstitial lung disease.
    Maher TM; Brown KK; Kreuter M; Devaraj A; Walsh SLF; Lancaster LH; Belloli EA; Padilla M; Behr J; Goeldner RG; Tetzlaff K; Schlenker-Herceg R; Flaherty KR;
    Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 34210788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease.
    Flaherty KR; Brown KK; Wells AU; Clerisme-Beaty E; Collard HR; Cottin V; Devaraj A; Inoue Y; Le Maulf F; Richeldi L; Schmidt H; Walsh S; Mezzanotte W; Schlenker-Herceg R
    BMJ Open Respir Res; 2017; 4(1):e000212. PubMed ID: 29018526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
    Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
    Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.
    Raghu G; van den Blink B; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Santin-Janin H; Mulder GJ; Bartholmai B; Gupta R; Richeldi L
    JAMA; 2018 Jun; 319(22):2299-2307. PubMed ID: 29800034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.